> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BMS’ Opdivo-Yervoy Combo for Mesothelioma
- URL: https://www.fdaweb.com/bms-opdivo-yervoy-combo-for-mesothelioma/
- Published: 2020-10-02T12:00:00.000Z
- Updated: 2026-09-14T16:31:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147795

FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for first-line treatment of adults with malignant pleural mesothelioma (MPM) that cannot be removed by surgery. An FDA [news release](https://www.fda.gov/news-events/press-announcements/fda-approves-drug-combination-treating-mesothelioma?ref=fdaweb.com) says this is the first drug regimen approved for mesothelioma in 16 years.

The drug combination was evaluated during a randomized, open-label trial in 605 patients with previously untreated unresectable MPM, FDA says. “At the time of the analysis, patients who received Opdivo in combination with Yervoy survived a median of 18.1 months while patients who underwent chemotherapy survived a median of 14.1 months,” it says. The most common side effects were fatigue, musculoskeletal pain, rash, diarrhea, dyspnea (difficulty breathing), nausea, decreased appetite, cough and pruritis (itching).